Pertussis vaccine in pregnant women: safety and uptake

Flor M Munoz
Department of Pediatrics, Section of Infectious Diseases, Baylor College of Medicine, Houston, TX, USA

Abstract: Pertussis continues to be an important cause of morbidity and mortality in children worldwide, particularly among infants too young to be vaccinated or who are unvaccinated and unprotected by naturally acquired passive antibodies from their mothers. Vaccination of women during pregnancy with an adult formulation of acellular pertussis vaccine in combination with tetanus and diphtheria toxoids (Tdap [tetanus, reduced diphtheria and acellular pertussis vaccine]) is recommended in several industrialized countries to boost the levels of maternal antibodies that are transferred transplacently and protect infants during the period of life when they are more likely to succumb to pertussis. Data from clinical and epidemiologic studies are supportive of the safety and effectiveness of maternal immunization with pertussis vaccines. Tdap is safe and well tolerated in pregnant women. Local and systemic reactogenicity is similar to that observed in nonpregnant adults, and no serious adverse events have been attributed to Tdap vaccination during pregnancy. Maternal antibodies elicited by the vaccine are efficiently transferred to the fetus through the placenta, and studies have consistently found that infants born to vaccinated mothers have significantly higher concentrations of pertussis antibodies than infants of nonvaccinated mothers. Although a correlate of protection against pertussis is unknown, higher concentrations of antibodies are likely to result in protection of young infants. A reduction in infant pertussis has been shown to occur when high vaccine coverage rates are achieved by pregnant women, as reported in the UK vaccination program. Furthermore, as more vaccine programs incorporate Tdap vaccination during pregnancy, prospective and epidemiologic data will be available to continuously assess the safety and efficacy of this intervention. Improving the uptake of pertussis vaccine among pregnant women remains a challenge that will require the joint effort of multiple stakeholders to improve education, access, and acceptability of the vaccine among pregnant mothers and providers.

Keywords: pertussis, vaccine, pregnancy, maternal immunization, safety, uptake

Introduction

Pertussis (whooping cough), a vaccine-preventable disease, is among the top ten causes of death among infants and young children worldwide.¹⁻³ With millions of patients affected by the illness, the World Health Organization (WHO) estimated in 2008 that up to 195,000 deaths were associated with pertussis in children younger than 5 years of age every year.¹ More recent estimates from the WHO’s Maternal and Child Epidemiology Estimation (MCEE) group and the GBD Study continue to place pertussis among the top causes of childhood mortality, resulting in an estimated 60,000 deaths in children 1 to 59 months of age annually (range 43,000–94,000 and 21,000–127,000, respectively).²,³ While the burden of disease and mortality are likely...
greater in the developing world, pertussis remains a public health threat even in countries with high vaccination coverage rates. Globally, most pertussis deaths continue to occur in infants who are unvaccinated, or too young to be vaccinated, usually in the first 6 months of life.

There are two types of pertussis vaccines: whole cell pertussis (wP) vaccines prepared from killed *Bordetella pertussis* bacteria of different strains utilizing different methods for inactivation depending on the manufacturer, and acellular pertussis (aP) vaccines prepared from highly purified antigenic components of *B. pertussis*, which vary in type and concentration depending on the manufacturer as well. The components of aP vaccines typically include pertussis toxin (PT), pertactin (PRN), filamentous hemagglutinin (FHA) and fimbriae (FIM) type 2 or 3 proteins. Both wP and aP vaccines used for pediatric immunization are combined with tetanus and diphtheria toxoids (DTPw [diphtheria, tetanus, and whole cell pertussis vaccine] or DTaP [diphtheria, tetanus, and acellular pertussis vaccine]), or with other vaccine antigens, and, at this time, are not available as pertussis-only monocomponent vaccines. Combination tetanus vaccines with reduced doses of diphtheria and pertussis components (Tdap [tetanus, reduced diphtheria and acellular pertussis vaccine]), to decrease reactogenicity, are available for use in adolescents and adults to boost antibody concentrations.

**Vaccination programs currently in use to provide protection against pertussis**

Pertussis vaccines (DTPw) introduced in the 1940s and utilized as part of the WHO’s Expanded Program on Immunization (EPI) since the 1970s resulted in a significant reduction in the incidence and mortality of pertussis in children. DTaP, a less reactogenic acellular pertussis vaccine, was introduced to the pediatric immunization schedule in the 1990s in several industrialized countries. A resurgence of cases of pertussis and infant mortality ensued, attributed in part to waning immunity and a relatively shorter term protection provided by acellular vaccines. A recent WHO report determined that among 19 countries reporting a resurgence of pertussis, the majority were seeing the results of natural cyclic pertussis epidemics paired with enhanced surveillance afforded by more sensitive polymerase chain reaction (PCR) diagnostic testing and increased awareness of the disease, while five countries experienced a true resurgence, namely the USA, the UK, Australia, Portugal, and Chile. Interestingly, all countries except Chile utilize aP vaccines for infant immunization. In the case of Chile and possibly other countries where wP vaccine is utilized, it is believed that increased reporting and decreased vaccine coverage explain the increase in pertussis. In countries where aP vaccine was utilized exclusively, cases of pertussis began to occur more frequently in adolescents and young adults, whose main role has been identified as reservoirs of *B. pertussis* and sources of transmission to infants too young to be vaccinated. The pertussis immunization schedule required adjustments to include a booster dose of Tdap vaccine in adolescents and adults in the USA in 2006. Despite prompt adoption of the adolescent booster dose and adequate vaccine uptake in this population, pertussis cases continued to increase reaching numbers not seen in over 40 years, as did infant mortality, during large outbreaks reported in the USA in the last decade. By 2008, a recommendation to vaccinate women immediately after giving birth as well as household contacts of newborns was instituted, in an attempt to provide protection to infants by preventing pertussis in their mothers and close contacts. However, ongoing outbreaks and rising incidence of pertussis eventually resulted in the 2012 recommendation by the Advisory Committee on Immunization Practices (ACIP) of the Centers for Disease Control and Prevention (CDC) to immunize all pregnant women with Tdap, regardless of their previous vaccination history. Vaccination of pregnant women was considered to be the most direct method of protection for newborns and infants in the first few months of life, through passive transfer of maternal antibody after administration of Tdap in the second or third trimester of gestation. Parallel epidemiologic observations and disease burden lead to a similar recommendation by the Department of Health in the UK in 2012, as a temporary outbreak response measure, and in certain high-risk situations (such as outbreaks) or regions of other countries such as Canada, Belgium, Australia, New Zealand, Israel, and Argentina, where maternal immunization with Tdap has been adopted to protect newborns from pertussis. The current pertussis immunization strategies recommended by ACIP in the USA, by the UK, and by WHO are shown in Table 1.

**Benefits and risks associated with pertussis vaccine during pregnancy**

It is important to note that recommendations for vaccination of pregnant women against pertussis were not based on data obtained from traditional large prospective randomized, placebo-controlled clinical trials. Pertussis immunization recommendations were adapted to include pregnant women in response to the high burden of disease and in infants too young to be vaccinated in countries that adopted this disease prevention strategy. In the USA and in the UK, large
outbreaks of pertussis occurred prior to 2012, despite the use of adolescent and postpartum Tdap vaccination in the USA, prompting the need for new prevention strategies.\(^{10,11}\)

Although pertussis vaccines are not specifically licensed for pregnant women, licensed vaccines can be administered during pregnancy when women or their fetus are at risk of exposure to an infection that poses a special risk to the mother or the infants, and vaccines that are safe and effective are available for use.\(^{14}\) Available epidemiologic data is supportive of the safety of Tdap vaccine in pregnancy, as are the results of several recent clinical trials. Furthermore, the UK experience provides reassuring results from a large population-based safety and efficacy surveillance system. Overall benefits and potential risks are summarized in Table 2.

Initial reports of the use of Tdap in pregnancy confirmed the adequate immune response of pregnant women to the vaccine and the efficient transplacental passage of antibodies to the infant. In an observational study conducted from October 2008 to December 2009 in an obstetric clinic at the University of Louisville, Gall et al compared 52 women who received Tdap in the second trimester of gestation and 52 unvaccinated mothers using recovered maternal and cord blood samples and showed that vaccinated mothers and their infants had significantly higher concentrations of antibodies to all pertussis vaccine antigens; transplacental transfer of antibody was efficient; and the odds of the infant being protected by PT, diphtheria, and tetanus antibodies were higher when mothers were vaccinated antepartum. The study reported that there were no adverse events to the vaccine.\(^{15}\)

Similarly, in an observational cohort study conducted during a pseudo-outbreak of pertussis at Darmouth-Hitchcock Medical Center, in New Hampshire, Hardy-Fairbanks et al followed a convenience sample of 16 women who received Tdap during pregnancy (any trimester) in 2006 and compared them to 54 unvaccinated pregnant women who delivered between March 2008 and February 2009.\(^{16}\) Although there was no mention of adverse outcomes, in this serological study (maternal – cord – infant), Tdap vaccination during pregnancy enhanced infant antibody concentrations against pertussis in the first months of life. At 7 months of age, after the primary series of infant vaccines, antibody concentrations to pertussis antigens (PT, FHA, PRN, but not FIM) were lower in infants born to mothers who were vaccinated during pregnancy, but this difference did not persist after booster immunization.

A multicenter, randomized, double blind, placebo-controlled clinical trial of Tdap in pregnancy was conducted in the USA from 2009 to 2012.\(^{17}\) Forty eight health women were randomized at a 2:1 ratio to receive Tdap or placebo injection during pregnancy (n=33) or crossover Tdap vaccination

---

### Table 1 Immunization schedules for the prevention of pertussis

<table>
<thead>
<tr>
<th>Target population</th>
<th>USA ACIP/CDC</th>
<th>UK</th>
<th>WHO</th>
</tr>
</thead>
<tbody>
<tr>
<td>Primary childhood</td>
<td>DTaP</td>
<td>DTaP</td>
<td>DTPw</td>
</tr>
<tr>
<td>series</td>
<td>2 months</td>
<td>2 months</td>
<td>6 weeks</td>
</tr>
<tr>
<td></td>
<td>4 months</td>
<td>3 months</td>
<td>10–14 weeks</td>
</tr>
<tr>
<td></td>
<td>6 months</td>
<td>4 months</td>
<td>14–18 weeks</td>
</tr>
<tr>
<td></td>
<td>12–18 months</td>
<td>3–6 years</td>
<td>1–6 years</td>
</tr>
<tr>
<td></td>
<td>4–6 years</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Adolescent</td>
<td>Tdap</td>
<td>Not recommended</td>
<td>Not recommended</td>
</tr>
<tr>
<td></td>
<td>11–12 years (up to 18 years catch up)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Adults</td>
<td>Tdap</td>
<td>Not recommended</td>
<td>Not recommended</td>
</tr>
<tr>
<td></td>
<td>One dose at any age, including persons over 65 years of age</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pregnant women</td>
<td>Tdap</td>
<td>Tdap</td>
<td>Not recommended</td>
</tr>
<tr>
<td></td>
<td>One dose at every pregnancy given at 27–36 weeks of gestation*</td>
<td>One dose at every pregnancy at 28–32 weeks of gestation (up to 38 weeks)</td>
<td></td>
</tr>
<tr>
<td>Other</td>
<td>Tdap</td>
<td>Not recommended</td>
<td>Tdap</td>
</tr>
<tr>
<td></td>
<td>Health care personnel</td>
<td></td>
<td>Health care personnel in countries with demonstrated high rates of nosocomial transmission</td>
</tr>
<tr>
<td></td>
<td>Contacts of infants</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Notes:** *Tdap should be administered postpartum in women who were not vaccinated during pregnancy. Breastfeeding is not a contraindication to vaccination. UK immunization schedule: [http://www.nhs.uk/conditions/vaccinations/pages/vaccination-schedule-age-checklist.aspx](http://www.nhs.uk/conditions/vaccinations/pages/vaccination-schedule-age-checklist.aspx).**

**Abbreviations:** ACIP, Advisory Committee on Immunization Practices; CDC, Centers for Disease Control and Prevention; DTaP, diphtheria, tetanus, and acellular pertussis vaccine; DTPw, diphtheria, tetanus, and whole cell pertussis vaccine; Tdap, tetanus, reduced diphtheria and acellular pertussis vaccine; WHO, World Health Organization.
Potential benefits

- Vaccination can prevent pertussis infection in the mother.
- Transplacental passage of maternal antibodies protects a healthy mother and pregnancy, resulting in a healthy fetus.

Potential risks

- Vaccine safety is important to consider including the risk of:
  - Fever
  - Systemic reactogenicity
  - Allergic/anaphylactic reactions
- There are no safety concerns reported to date with the use of Tdap vaccine in pregnancy.

Use of vaccines in the second or third trimester of gestation minimizes any potential risk of embryotoxicity or teratogenicity.

High levels of maternal antibody may interfere with the infant's ability to respond to active immunization with high concentrations of antibody. However, priming with active immunization is preserved, and infants of mothers who are vaccinated with Tdap display an adequate booster response to vaccination.

Use of live vaccines should be avoided given theoretical risk of infection to the fetus (no live vaccines are currently in use for pertussis prevention).

There are no theoretical safety concerns with the use of effective inactivated vaccines during pregnancy.

Recent clinical studies evaluating Tdap in pregnant women in Canada, Belgium, and Vietnam have been completed.

At least three other prospective, randomized clinical studies are in progress or planned to continue to assess the safety and effectiveness of maternal immunization with Tdap.

The safety of Tdap in pregnancy has been assessed by several retrospective database and observational studies. Shakib et al reported no significant differences on the incidence of spontaneous or elective abortion, preterm delivery, gestational age, birth weight, congenital anomalies, or complex medical conditions after birth in a retrospective cohort of 138 women.

Newborns receive high concentrations of antibodies when mothers are vaccinated during the second or third trimester of gestation.

The half-life of the passively acquired antibodies is such that high concentrations are still present at 2 months of age, when routine infant vaccination against pertussis begins. Infants may also benefit from breast milk antibodies which are found in high concentrations after maternal vaccination.

Vaccination of women during pregnancy provides the most direct and efficient protection to newborns and young infants against pertussis.

### Table 2 Potential benefits and risks of pertussis vaccination during pregnancy

<table>
<thead>
<tr>
<th>Target population</th>
<th>Potential benefits</th>
<th>Potential risks</th>
</tr>
</thead>
<tbody>
<tr>
<td>Maternal immunization in general</td>
<td>Mothers are capable of responding to vaccine antigens and achieve antibody concentrations similar to those of nonpregnant adults. Mothers have regular access to medical care and several opportunities to receive immunizations during pregnancy. Prevention of infection is part of good health maintenance in a mother and of a healthy pregnancy.</td>
<td>Information regarding maternal immunization in general is based mostly on observational studies, epidemiologic studies, and small clinical trials. However, surveillance systems are in place to evaluate the safety of vaccines recommended in pregnancy, including Tdap, and large clinical trials are in progress or planned to continue to assess the safety and effectiveness of maternal immunization with Tdap.</td>
</tr>
</tbody>
</table>
| Mother                      | Vaccination can prevent pertussis infection in the mother. Prevention of the consequences of infection that may affect the pregnancy, such as fever, preterm labor, or preterm delivery, are a result of vaccination.                                                                 | Vaccine safety is important to consider including the risk of:
  - Fever
  - Systemic reactogenicity
  - Allergic/anaphylactic reactions
  There are no safety concerns reported to date with the use of Tdap vaccine in pregnancy. |
| Fetus                       | A healthy mother and pregnancy results in a healthy fetus that is more likely to grow and complete a term pregnancy. Use of vaccines in the second or third trimester of gestation minimizes any potential risk of embryotoxicity or teratogenicity.                                                                                     | Use of live vaccines should be avoided given theoretical risk of infection to the fetus (no live vaccines are currently in use for pertussis prevention). |
| Newborn and infant          | Transplacental passage of maternal antibodies protects infants against pertussis infection before they are able to be immunized. Newborns receive high concentrations of antibodies when mothers are vaccinated during the second or third trimester of gestation. The half-life of the passively acquired antibodies is such that high concentrations are still present at 2 months of age, when routine infant vaccination against pertussis begins. Infants may also benefit from breast milk antibodies which are found in high concentrations after maternal vaccination. Vaccination of women during pregnancy provides the most direct and efficient protection to newborns and young infants against pertussis. | High levels of maternal antibody may interfere with the infant's ability to respond to active immunization with high concentrations of antibody. However, priming with active immunization is preserved, and infants of mothers who are vaccinated with Tdap display an adequate booster response to vaccination. |

**Abbreviation:** Tdap, tetanus, reduced diphtheria and acellular pertussis vaccine.
who received Tdap during pregnancy (two-thirds in the first trimester of gestation) and their infants and 552 mother–infant pair controls during 2005–2009. Concurrently, during a time when Tdap was not routinely recommended in pregnancy from 2005 to 2010, the vaccine safety adverse event reporting system (VAERS) did not identify any concerning patterns in maternal, infant, or fetal outcomes among 132 reports of Tdap administered to pregnant women (77.3% during the first trimester), and the pregnancy registry for Adacel™ did not find increase in the incidence of spontaneous abortion or preterm deliveries among 539 reports of vaccine receipt during pregnancy. An observational cohort study carried out by Kharbanda et al after the 2010 California outbreak used electronic medical record and claims data from seven Vaccine Safety Datalink sites to identify 26,229 women who received Tdap vaccine during pregnancy and compared their outcomes with 97,265 who did not. Tdap vaccination was not associated with increased risks of adverse birth outcomes in this cohort, specifically preterm birth and small for gestational age (SGA) infant birth, and hypertensive disorders of pregnancy in the mother. A slightly higher incidence of chorioamnionitis was observed in the group of mothers vaccinated during pregnancy compared to the nonvaccinated cohort (6.1% vs 5.5%), but this difference was not statistically significant. Finally, the safety report from the UK maternal Tdap vaccination program is consistent with the experience in the USA. Donegan et al followed 20,074 women who received Tdap in the third trimester of pregnancy using the UK Clinical Practice Research Datalink and compared them to a historical unvaccinated control group. Adverse events reported during pregnancy and delivery were evaluated, with stillbirth as the primary outcome. Investigators did not find an increased risk of stillbirth in the 14 days after vaccination (incidence rate ratio 0.69, 95% confidence interval [CI] 0.23–1.62) or later in pregnancy (0.85, 0.44–1.61) compared with historical national rates. There was no evidence that vaccination accelerated the time to delivery, nor of an increased risk of stillbirth, maternal or neonatal death, pre-eclampsia or eclampsia, hemorrhage, fetal distress, uterine rupture, placenta or vasa previa, cesarean delivery, low birth weight, or neonatal renal failure. Congenital anomalies were not sought, but they are being followed through condition-specific registries.

Impact and uptake of pertussis vaccine in pregnant women

Vaccination during pregnancy is expected to be more effective in reducing the risk of pertussis in young infants than vaccination of the mother postpartum, or cocooning strategies that include the father and one additional caretaker. In study by Terranella et al, pregnancy vaccination with Tdap was estimated to be able to reduce infant pertussis cases by 33% vs 20% with postpartum vaccination, infant hospitalizations by 38% vs 19%, and infant deaths by 49% vs 16%. In the USA, postpartum vaccination continues to be recommended for women who do not receive Tdap during pregnancy, as additional benefit in reducing the impact of infant pertussis can be achieved, albeit at a higher cost. Of note, antibody responses after Tdap vaccination in women of childbearing age and postpartum women only begin to increase 5–7 days after immunization, and although they reach peak levels by day 14 after vaccination, this response might not be rapid enough to provide protection to mothers who are vaccinated close to their date of delivery or postpartum, or to their infants who are often exposed shortly after delivery. Considering that active placental transport of maternal antibody to the fetus occurs predominantly from the 28th week of gestation onward and that vaccination shortly prior to delivery is not likely to allow sufficient time for the transfer of antibodies, the suggested optimal time for Tdap vaccination is in the late second trimester to early in the third trimester. However, the vaccine can be given at any time during pregnancy and up to delivery.

Pertussis vaccination is recommended with each pregnancy to boost maternal antibody concentrations and ensure maximal protection to every newborn, independently from the number and timing of prior pregnancies. Vaccine-induced pertussis antibodies wane over time and the protective antibody level required in newborn infants or the quality of protection afforded is unknown. Vaccine-induced pertussis antibodies measured in paired maternal and umbilical cord serum show significant decay over a 2-year interval between pregnancies. However, pertussis antibody levels in the cord blood of infants whose mothers were vaccinated ~13 months earlier (following the birth of an older sibling) were found to be significantly higher than those in cord blood of the older sibling prior to maternal vaccination. Some investigators are currently working on assessing the relative avidity index (RAI) of anti-PT antibodies in maternal and cord sera after maternal immunization with Tdap. Furthermore, the role of cell-mediated immune responses needs to be better understood. Huygen et al have proposed that although Tdap vaccination increases vaccine-specific IgG antibodies to the same extent in pregnant and nonpregnant women, the stimulation of vaccine-specific Th1 type cellular immune responses appear to be transient and impaired during pregnancy, as only tetanus toxin-specific but not pertussis antigen-specific T-cell responses were elicited in pregnant
subjects 1 month after vaccination. Lastly, infant protection through breast milk antibodies is a potential additional benefit from maternal immunization that continues to be studied.

The uptake of Tdap in pregnant women in the USA during the 2010 California outbreak and prior to the 2012 ACIP recommendation to immunize all women during pregnancy varied from 15.9% to 30%. The uptake after the 2012 recommendation has been reported to be similar. A CDC study utilizing the Pregnancy Risk Assessment Monitoring System (PRAMS) provided an estimate median percentage of 55.7% (range 38.2%–76.6%) of women with live births receiving Tdap vaccine at some point before, during, or after a live birth in one of 16 states of New York City in the USA in 2011. Less than 10% accounted for vaccinations given during pregnancy. In the UK, rapid uptake of vaccine was achieved in the first year after introduction of the Tdap maternal immunization priority program, and rates of greater than 70% were reported. High coverage rates have been proven difficult to maintain, even in a system where vaccinations can be provided at no cost to the patient during routine prenatal care. Current estimates of coverage in the UK are just below 60%, and regularly updated data for England are available at https://www.gov.uk/government/collections/vaccine-uptake/pertussis-vaccine-uptake-in-pregnant-women.

Perhaps, the most significant contribution to the efforts of preventing infantile pertussis through maternal immunization has been the efficacy data generated from the UK vaccination program. A vaccine effectiveness of at least 90% is expected among infants 2–3 months of age when maternal pertussis vaccine is administered at least 7 days or more prior to delivery. This is an effectiveness that is similar to that achieved by active infant vaccination. The UK program is also an important source of data to understand what works and what needs to be improved when implementing a new program of vaccination during pregnancy. While in the USA, prenatal care is provided by obstetricians for the majority of pregnant women, most women in the UK are cared for by general care physicians and midwives, who follow only healthy mothers, not those with complications. Access to the vaccine and to information and a standard recommendation are important elements in the implementation of a maternal vaccination program.

**Strategies to promote the uptake of vaccination against pertussis in pregnant women**

A recommendation alone is not sufficient to achieve adequate coverage of vaccines in general, particularly among pregnant women. Patients and providers need a substantial amount of information, education, and support to understand the rationale behind this new vaccination strategy. This is especially true when the target population, pregnant women, is considered to be a vulnerable group who is not usually offered vaccines, with the exception of tetanus toxoid or influenza vaccine, which are used inconsistently in different geographic regions and health systems. Awareness of the current problem of pertussis, its effects on morbidity and mortality in newborns and young infants, and the limitations of the current preventive strategies is an important first step. In general, obstetricians and providers of prenatal and delivery care are less likely to be informed of this primarily pediatric issue; yet, they are the most important resource to the pregnant mother because of the special situation that pertussis infection in early life requires an intervention during pregnancy. In most settings, the recommendation to receive Tdap vaccine during pregnancy is most effective when received by the pregnant mother from her obstetric or prenatal care provider. In a number of surveys for influenza vaccine, and more recently for Tdap vaccine, most pregnant women would accept the vaccination if offered by their health care provider.

Considering the complexity of the decision making processes a mother faces during her pregnancy, it is important that providers are able to establish an efficient communication and a relationship of trust. Most women recognize their vulnerability as well as the intense responsibility they assume when embarking on a pregnancy. Every decision is made in the context of the woman’s cultural background, personal beliefs, fears, insecurities, values, and level of education, among other factors. In the current era of instant access to information and also hesitancy for immunizations, women are influenced by information about vaccines they are able to obtain from many sources, some of which will reinforce their skepticism, while some will be supportive. Being aware of these dynamics is important for the health care provider to be able to dedicate the time needed to discuss options and provide continued education to their pregnant patient. An engaged provider will be more valuable than the simple act of sharing facts and results of scientific studies that, although supportive of the safety and efficacy of the vaccine, might be meaningless for a pregnant mother who is concerned with the safety of her child. Once an initial communication has been established, the use of tools such as phone or text reminders, website access, and other methods of continuing education would be appropriate.

Access to the vaccine is the third element of a successful vaccination program. It is clear from the experience with
influenza vaccination in pregnancy that the highest uptake is achieved when the vaccine is recommended and given at the prenatal care practice, compared to when it is recommended and not offered on site.\textsuperscript{39} This paradigm is anticipated to work also for Tdap, where ideally health care providers will have the vaccine on site at their offices and will be able to administer the vaccination at any time during routine prenatal care visits. The necessary elements to achieve this practice include the establishment of the obstetric/prenatal care office as a vaccine provider site. This can be accomplished through different methods, from having a designated vaccinator and all the appropriate equipment in the clinic, to utilizing multidisciplinary clinic resources including a pharmacy or vaccine clinic that are in the same premises. This is better than relying on the mother to search for a place that would provide her with the vaccination while pregnant, given misconceptions regarding risk and liability concerns. Tools for providers and patients are available from sources such as the CDC and the American Congress of Obstetrics and Gynecology.\textsuperscript{40}

**Conclusion**

Pertussis is a vaccine-preventable disease that continues to cause significant morbidity and infant mortality worldwide. wP and aP vaccines are available for the prevention of pertussis in infants starting at 2 months of age through adolescence, while reduced-dose aP vaccines in combination with tetanus toxoid and diphtheria toxoids are recommended for immunization of adults. Vaccination of women during pregnancy is more likely to provide protection to the newborn infant than preconception or postpartum vaccination. Health authorities in several industrialized countries have recommended that women receive Tdap during every pregnancy, independent from previous vaccination or number of pregnancies, in order to provide each newborn with the highest possible concentration of antibodies to pertussis at birth and reduce the risk of early acquisition of pertussis infection, severe disease, and mortality. Tdap vaccine has been shown to be well tolerated and safe in pregnant women. Early studies have demonstrated adequate immune responses to the vaccine antigens in pregnant women, efficient transplacental antibody transfer, and high concentrations of pertussis antibodies in infants of vaccinated mothers that last until the infant’s first series of pertussis vaccines begins. A relative reduction in vaccine-specific antibody concentrations after completion of the primary series of immunizations has been reported in infants born to mothers vaccinated with Tdap during pregnancy. However, priming and boost responses remain intact, and infants are likely to benefit due to protection from significantly higher concentrations of pertussis antibodies in the first 2 months of life. Uptake of Tdap vaccine among pregnant women has been less than optimal in countries that have adopted this practice, even when vaccine is provided to pregnant women as part of their routine prenatal care. The most important component of a successful vaccination program for pregnant women hinges on the recommendation from their obstetric or prenatal care provider to receive the vaccine. Engaging in a discussion to explain the reason and need for Tdap immunization during pregnancy, and to discuss the safety and effectiveness information available to date, as well as providing easy access to the vaccine are key elements to improve coverage of pertussis vaccines in pregnancy and protection of infants against pertussis.

**Disclosure**

The author has no conflicts of interest to report in relation to this paper.

**References**


